RRP ISA Survey Results

    (Important Disclaimer)


    Educational Sweet Spot

    Kudos to Nventa Biopharmaceuticals Corp. (maker of HspE7) for their work in developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV) AND for the educational information presented on their website on "Serious HPV-Related Diseases" including Head and Neck Cancers and Recurrent Respiratory Papillomatosis. It's nice to see a pharmaceutical company taking the lead in educating the public that HPV causes more than cervical cancer.

    The statistics are staggering as reported on their website: The majority of HPV-positive tumors contained the “high risk” HPV types 16 (70-90 percent) and 18 (5-34 percent, depending on location); Among head and neck sites, HPV was most often detected in tumors of the oropharynx (33-39 percent), followed by the oral cavity (22-25 percent) and larynx (22-26 percent). These cancers are treated with surgery and with primary radiation therapy.